CA2575462A1 - Mutations dans des erb2 associee a des phenotypes cancereux - Google Patents

Mutations dans des erb2 associee a des phenotypes cancereux Download PDF

Info

Publication number: CA2575462A1
Authority: CA; Canada
Prior art keywords: erbb2; nucleic acid; mutation; sample; mutant
Prior art date: 2004-07-30
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002575462A

Other languages

English (en)

Inventor

Michael Stratton

Andrew Futreal

Richard Wooster

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Wellcome Trust Ltd

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-07-30

Filing date

2005-07-29

Publication date

2006-02-02

2004-07-30 Priority claimed from GBGB0417107.0A external-priority patent/GB0417107D0/en

2005-07-29 Application filed by Individual filed Critical Individual

2006-02-02 Publication of CA2575462A1 publication Critical patent/CA2575462A1/fr

Status Abandoned legal-status Critical Current

Links

230000035772 mutation Effects 0.000 title claims abstract description 156
206010028980 Neoplasm Diseases 0.000 claims abstract description 76
108090000623 proteins and genes Proteins 0.000 claims abstract description 66
201000011510 cancer Diseases 0.000 claims abstract description 24
108090000765 processed proteins & peptides Proteins 0.000 claims description 177
102000004196 processed proteins & peptides Human genes 0.000 claims description 156
229920001184 polypeptide Polymers 0.000 claims description 147
150000007523 nucleic acids Chemical class 0.000 claims description 129
102000039446 nucleic acids Human genes 0.000 claims description 124
108020004707 nucleic acids Proteins 0.000 claims description 124
238000000034 method Methods 0.000 claims description 114
238000003199 nucleic acid amplification method Methods 0.000 claims description 53
230000003321 amplification Effects 0.000 claims description 52
150000001875 compounds Chemical class 0.000 claims description 49
238000003780 insertion Methods 0.000 claims description 42
230000037431 insertion Effects 0.000 claims description 42
150000001413 amino acids Chemical class 0.000 claims description 40
238000003556 assay Methods 0.000 claims description 40
239000000463 material Substances 0.000 claims description 37
238000001514 detection method Methods 0.000 claims description 35
102000004169 proteins and genes Human genes 0.000 claims description 34
230000027455 binding Effects 0.000 claims description 31
239000000427 antigen Substances 0.000 claims description 30
108091007433 antigens Proteins 0.000 claims description 30
102000036639 antigens Human genes 0.000 claims description 30
230000000694 effects Effects 0.000 claims description 30
230000001413 cellular effect Effects 0.000 claims description 29
239000003550 marker Substances 0.000 claims description 26
239000012634 fragment Substances 0.000 claims description 25
208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 22
238000002560 therapeutic procedure Methods 0.000 claims description 18
239000003446 ligand Substances 0.000 claims description 16
230000008569 process Effects 0.000 claims description 15
238000006467 substitution reaction Methods 0.000 claims description 14
230000001419 dependent effect Effects 0.000 claims description 13
239000000758 substrate Substances 0.000 claims description 13
108060003951 Immunoglobulin Proteins 0.000 claims description 10
102000018358 immunoglobulin Human genes 0.000 claims description 10
238000012216 screening Methods 0.000 claims description 10
239000003112 inhibitor Substances 0.000 claims description 8
230000004048 modification Effects 0.000 claims description 8
238000012986 modification Methods 0.000 claims description 8
238000012163 sequencing technique Methods 0.000 claims description 8
238000002965 ELISA Methods 0.000 claims description 7
102000004190 Enzymes Human genes 0.000 claims description 7
108090000790 Enzymes Proteins 0.000 claims description 7
108091000080 Phosphotransferase Proteins 0.000 claims description 7
229940022353 herceptin Drugs 0.000 claims description 7
102000020233 phosphotransferase Human genes 0.000 claims description 7
230000000295 complement effect Effects 0.000 claims description 5
230000003993 interaction Effects 0.000 claims description 5
231100000590 oncogenic Toxicity 0.000 claims description 5
230000002246 oncogenic effect Effects 0.000 claims description 5
238000007405 data analysis Methods 0.000 claims description 4
238000003860 storage Methods 0.000 claims description 4
125000003275 alpha amino acid group Chemical group 0.000 claims 2
230000001028 anti-proliverative effect Effects 0.000 claims 2
238000003745 diagnosis Methods 0.000 abstract description 11
238000011161 development Methods 0.000 abstract description 5
238000011319 anticancer therapy Methods 0.000 abstract description 2
239000002246 antineoplastic agent Substances 0.000 abstract description 2
210000004027 cell Anatomy 0.000 description 98
108020004414 DNA Proteins 0.000 description 53
239000000523 sample Substances 0.000 description 37
239000013615 primer Substances 0.000 description 27
238000003752 polymerase chain reaction Methods 0.000 description 22
210000001519 tissue Anatomy 0.000 description 21
208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 21
239000013598 vector Substances 0.000 description 19
239000000872 buffer Substances 0.000 description 18
230000014509 gene expression Effects 0.000 description 16
102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 15
108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 15
YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 15
238000006243 chemical reaction Methods 0.000 description 13
239000000047 product Substances 0.000 description 12
208000009956 adenocarcinoma Diseases 0.000 description 11
238000004458 analytical method Methods 0.000 description 11
239000003795 chemical substances by application Substances 0.000 description 11
239000013078 crystal Substances 0.000 description 11
210000004408 hybridoma Anatomy 0.000 description 11
239000002609 medium Substances 0.000 description 11
239000002773 nucleotide Substances 0.000 description 11
125000003729 nucleotide group Chemical group 0.000 description 11
230000001376 precipitating effect Effects 0.000 description 11
102000053602 DNA Human genes 0.000 description 10
238000001727 in vivo Methods 0.000 description 10
108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 9
230000015572 biosynthetic process Effects 0.000 description 9
238000004113 cell culture Methods 0.000 description 9
238000002425 crystallisation Methods 0.000 description 9
238000012217 deletion Methods 0.000 description 9
230000037430 deletion Effects 0.000 description 9
239000012528 membrane Substances 0.000 description 9
238000002360 preparation method Methods 0.000 description 9
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 8
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 8
230000000890 antigenic effect Effects 0.000 description 8
239000000203 mixture Substances 0.000 description 8
210000002966 serum Anatomy 0.000 description 8
238000001890 transfection Methods 0.000 description 8
241000699670 Mus sp. Species 0.000 description 7
108091028043 Nucleic acid sequence Proteins 0.000 description 7
206010035226 Plasma cell myeloma Diseases 0.000 description 7
238000009792 diffusion process Methods 0.000 description 7
238000009396 hybridization Methods 0.000 description 7
238000003018 immunoassay Methods 0.000 description 7
238000000338 in vitro Methods 0.000 description 7
201000000050 myeloid neoplasm Diseases 0.000 description 7
230000002018 overexpression Effects 0.000 description 7
102000016914 ras Proteins Human genes 0.000 description 7
108010014186 ras Proteins Proteins 0.000 description 7
238000012360 testing method Methods 0.000 description 7
108020004705 Codon Proteins 0.000 description 6
108020004635 Complementary DNA Proteins 0.000 description 6
230000001580 bacterial effect Effects 0.000 description 6
238000010804 cDNA synthesis Methods 0.000 description 6
238000005516 engineering process Methods 0.000 description 6
229940088598 enzyme Drugs 0.000 description 6
150000002611 lead compounds Chemical class 0.000 description 6
238000003127 radioimmunoassay Methods 0.000 description 6
239000000243 solution Substances 0.000 description 6
230000009466 transformation Effects 0.000 description 6
238000005406 washing Methods 0.000 description 6
238000001262 western blot Methods 0.000 description 6
206010006187 Breast cancer Diseases 0.000 description 5
208000026310 Breast neoplasm Diseases 0.000 description 5
241000588724 Escherichia coli Species 0.000 description 5
102100034343 Integrase Human genes 0.000 description 5
241001465754 Metazoa Species 0.000 description 5
108091034117 Oligonucleotide Proteins 0.000 description 5
108700020796 Oncogene Proteins 0.000 description 5
108020004511 Recombinant DNA Proteins 0.000 description 5
240000004808 Saccharomyces cerevisiae Species 0.000 description 5
235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 5
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 5
230000008859 change Effects 0.000 description 5
239000002299 complementary DNA Substances 0.000 description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
230000002255 enzymatic effect Effects 0.000 description 5
230000004927 fusion Effects 0.000 description 5
239000001963 growth medium Substances 0.000 description 5
239000011159 matrix material Substances 0.000 description 5
239000013612 plasmid Substances 0.000 description 5
102000040430 polynucleotide Human genes 0.000 description 5
108091033319 polynucleotide Proteins 0.000 description 5
239000002157 polynucleotide Substances 0.000 description 5
XOJVVFBFDXDTEG-UHFFFAOYSA-N pristane Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 description 5
238000000746 purification Methods 0.000 description 5
108091008146 restriction endonucleases Proteins 0.000 description 5
150000003384 small molecules Chemical class 0.000 description 5
230000000392 somatic effect Effects 0.000 description 5
210000004989 spleen cell Anatomy 0.000 description 5
230000001225 therapeutic effect Effects 0.000 description 5
238000009007 Diagnostic Kit Methods 0.000 description 4
101150029707 ERBB2 gene Proteins 0.000 description 4
241000124008 Mammalia Species 0.000 description 4
241001529936 Murinae Species 0.000 description 4
229930012538 Paclitaxel Natural products 0.000 description 4
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
239000002202 Polyethylene glycol Substances 0.000 description 4
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 4
230000004913 activation Effects 0.000 description 4
238000007792 addition Methods 0.000 description 4
239000002671 adjuvant Substances 0.000 description 4
238000001042 affinity chromatography Methods 0.000 description 4
230000000903 blocking effect Effects 0.000 description 4
-1 cationic lipid Chemical class 0.000 description 4
238000004587 chromatography analysis Methods 0.000 description 4
238000003776 cleavage reaction Methods 0.000 description 4
230000018109 developmental process Effects 0.000 description 4
201000010099 disease Diseases 0.000 description 4
238000006073 displacement reaction Methods 0.000 description 4
238000001962 electrophoresis Methods 0.000 description 4
230000006870 function Effects 0.000 description 4
239000000499 gel Substances 0.000 description 4
230000012010 growth Effects 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000007924 injection Substances 0.000 description 4
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
210000004962 mammalian cell Anatomy 0.000 description 4
238000004519 manufacturing process Methods 0.000 description 4
229960001592 paclitaxel Drugs 0.000 description 4
230000000865 phosphorylative effect Effects 0.000 description 4
229920001223 polyethylene glycol Polymers 0.000 description 4
230000002285 radioactive effect Effects 0.000 description 4
230000010076 replication Effects 0.000 description 4
150000003839 salts Chemical class 0.000 description 4
230000007017 scission Effects 0.000 description 4
230000003248 secreting effect Effects 0.000 description 4
239000007787 solid Substances 0.000 description 4
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 4
206010069754 Acquired gene mutation Diseases 0.000 description 3
241000894006 Bacteria Species 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
108091027305 Heteroduplex Proteins 0.000 description 3
101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 3
102000003960 Ligases Human genes 0.000 description 3
108090000364 Ligases Proteins 0.000 description 3
206010058467 Lung neoplasm malignant Diseases 0.000 description 3
102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 3
102000043276 Oncogene Human genes 0.000 description 3
102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 3
108020004682 Single-Stranded DNA Proteins 0.000 description 3
239000002253 acid Substances 0.000 description 3
125000000539 amino acid group Chemical group 0.000 description 3
210000004102 animal cell Anatomy 0.000 description 3
230000002072 anti-mutant effect Effects 0.000 description 3
230000002788 anti-peptide Effects 0.000 description 3
230000006907 apoptotic process Effects 0.000 description 3
238000013459 approach Methods 0.000 description 3
239000011324 bead Substances 0.000 description 3
210000001124 body fluid Anatomy 0.000 description 3
230000004663 cell proliferation Effects 0.000 description 3
238000012875 competitive assay Methods 0.000 description 3
230000000875 corresponding effect Effects 0.000 description 3
239000003814 drug Substances 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
230000002068 genetic effect Effects 0.000 description 3
238000001114 immunoprecipitation Methods 0.000 description 3
238000002955 isolation Methods 0.000 description 3
201000005202 lung cancer Diseases 0.000 description 3
208000020816 lung neoplasm Diseases 0.000 description 3
108010026228 mRNA guanylyltransferase Proteins 0.000 description 3
230000001404 mediated effect Effects 0.000 description 3
238000002703 mutagenesis Methods 0.000 description 3
231100000350 mutagenesis Toxicity 0.000 description 3
230000001613 neoplastic effect Effects 0.000 description 3
230000037361 pathway Effects 0.000 description 3
230000026731 phosphorylation Effects 0.000 description 3
238000006366 phosphorylation reaction Methods 0.000 description 3
230000003389 potentiating effect Effects 0.000 description 3
108700042226 ras Genes Proteins 0.000 description 3
238000002864 sequence alignment Methods 0.000 description 3
238000000638 solvent extraction Methods 0.000 description 3
230000037439 somatic mutation Effects 0.000 description 3
239000000126 substance Substances 0.000 description 3
238000011282 treatment Methods 0.000 description 3
241001515965 unidentified phage Species 0.000 description 3
210000005253 yeast cell Anatomy 0.000 description 3
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
102000002260 Alkaline Phosphatase Human genes 0.000 description 2
108020004774 Alkaline Phosphatase Proteins 0.000 description 2
108010039627 Aprotinin Proteins 0.000 description 2
206010055113 Breast cancer metastatic Diseases 0.000 description 2
208000005623 Carcinogenesis Diseases 0.000 description 2
108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 2
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
102100024829 DNA polymerase delta catalytic subunit Human genes 0.000 description 2
229920002307 Dextran Polymers 0.000 description 2
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
241000238631 Hexapoda Species 0.000 description 2
108010093488 His-His-His-His-His-His Proteins 0.000 description 2
101000868333 Homo sapiens Cyclin-dependent kinase 1 Proteins 0.000 description 2
101000909198 Homo sapiens DNA polymerase delta catalytic subunit Proteins 0.000 description 2
101001126417 Homo sapiens Platelet-derived growth factor receptor alpha Proteins 0.000 description 2
108010001336 Horseradish Peroxidase Proteins 0.000 description 2
AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 2
102000004877 Insulin Human genes 0.000 description 2
108090001061 Insulin Proteins 0.000 description 2
239000005411 L01XE02 - Gefitinib Substances 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
206010033128 Ovarian cancer Diseases 0.000 description 2
206010061535 Ovarian neoplasm Diseases 0.000 description 2
102100030485 Platelet-derived growth factor receptor alpha Human genes 0.000 description 2
108010076504 Protein Sorting Signals Proteins 0.000 description 2
102000052575 Proto-Oncogene Human genes 0.000 description 2
108700020978 Proto-Oncogene Proteins 0.000 description 2
208000005718 Stomach Neoplasms Diseases 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
101710137500 T7 RNA polymerase Proteins 0.000 description 2
241000700605 Viruses Species 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
239000000654 additive Substances 0.000 description 2
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
229910052921 ammonium sulfate Inorganic materials 0.000 description 2
239000001166 ammonium sulphate Substances 0.000 description 2
235000011130 ammonium sulphate Nutrition 0.000 description 2
210000003567 ascitic fluid Anatomy 0.000 description 2
238000002820 assay format Methods 0.000 description 2
230000008901 benefit Effects 0.000 description 2
239000012472 biological sample Substances 0.000 description 2
239000010839 body fluid Substances 0.000 description 2
239000001506 calcium phosphate Substances 0.000 description 2
229910000389 calcium phosphate Inorganic materials 0.000 description 2
235000011010 calcium phosphates Nutrition 0.000 description 2
238000004364 calculation method Methods 0.000 description 2
230000036952 cancer formation Effects 0.000 description 2
231100000504 carcinogenesis Toxicity 0.000 description 2
230000003197 catalytic effect Effects 0.000 description 2
238000000423 cell based assay Methods 0.000 description 2
230000024245 cell differentiation Effects 0.000 description 2
239000013592 cell lysate Substances 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
238000010367 cloning Methods 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
238000000576 coating method Methods 0.000 description 2
230000002860 competitive effect Effects 0.000 description 2
238000004590 computer program Methods 0.000 description 2
108091036078 conserved sequence Proteins 0.000 description 2
239000012228 culture supernatant Substances 0.000 description 2
238000012258 culturing Methods 0.000 description 2
238000001212 derivatisation Methods 0.000 description 2
238000013461 design Methods 0.000 description 2
230000004069 differentiation Effects 0.000 description 2
239000012636 effector Substances 0.000 description 2
239000013604 expression vector Substances 0.000 description 2
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
239000007850 fluorescent dye Substances 0.000 description 2
108020001507 fusion proteins Proteins 0.000 description 2
102000037865 fusion proteins Human genes 0.000 description 2
206010017758 gastric cancer Diseases 0.000 description 2
229960002584 gefitinib Drugs 0.000 description 2
XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 2
210000004602 germ cell Anatomy 0.000 description 2
238000003505 heat denaturation Methods 0.000 description 2
229910001385 heavy metal Inorganic materials 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
210000004754 hybrid cell Anatomy 0.000 description 2
230000028993 immune response Effects 0.000 description 2
210000000987 immune system Anatomy 0.000 description 2
230000002163 immunogen Effects 0.000 description 2
230000005847 immunogenicity Effects 0.000 description 2
229940072221 immunoglobulins Drugs 0.000 description 2
238000011065 in-situ storage Methods 0.000 description 2
238000011534 incubation Methods 0.000 description 2
230000000977 initiatory effect Effects 0.000 description 2
229940125396 insulin Drugs 0.000 description 2
239000011630 iodine Substances 0.000 description 2
229910052740 iodine Inorganic materials 0.000 description 2
239000012139 lysis buffer Substances 0.000 description 2
238000012544 monitoring process Methods 0.000 description 2
229910000489 osmium tetroxide Inorganic materials 0.000 description 2
239000012285 osmium tetroxide Substances 0.000 description 2
230000036961 partial effect Effects 0.000 description 2
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
229920002401 polyacrylamide Polymers 0.000 description 2
102000054765 polymorphisms of proteins Human genes 0.000 description 2
238000010837 poor prognosis Methods 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
238000012545 processing Methods 0.000 description 2
230000002062 proliferating effect Effects 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
230000001177 retroviral effect Effects 0.000 description 2
238000003757 reverse transcription PCR Methods 0.000 description 2
PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 2
102220282390 rs80357419 Human genes 0.000 description 2
230000019491 signal transduction Effects 0.000 description 2
239000001488 sodium phosphate Substances 0.000 description 2
229910000162 sodium phosphate Inorganic materials 0.000 description 2
125000006850 spacer group Chemical group 0.000 description 2
201000011549 stomach cancer Diseases 0.000 description 2
150000003467 sulfuric acid derivatives Chemical class 0.000 description 2
229910021653 sulphate ion Inorganic materials 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
GKLVYJBZJHMRIY-UHFFFAOYSA-N technetium atom Chemical compound [Tc] GKLVYJBZJHMRIY-UHFFFAOYSA-N 0.000 description 2
230000001131 transforming effect Effects 0.000 description 2
238000013519 translation Methods 0.000 description 2
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
230000000381 tumorigenic effect Effects 0.000 description 2
238000003160 two-hybrid assay Methods 0.000 description 2
239000011534 wash buffer Substances 0.000 description 2
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 1
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
108091093088 Amplicon Proteins 0.000 description 1
108091023037 Aptamer Proteins 0.000 description 1
241000972773 Aulopiformes Species 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
239000004215 Carbon black (E152) Substances 0.000 description 1
102000014914 Carrier Proteins Human genes 0.000 description 1
108010078791 Carrier Proteins Proteins 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 1
102000012410 DNA Ligases Human genes 0.000 description 1
108010061982 DNA Ligases Proteins 0.000 description 1
239000003155 DNA primer Substances 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
101100118093 Drosophila melanogaster eEF1alpha2 gene Proteins 0.000 description 1
208000006402 Ductal Carcinoma Diseases 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
102000001301 EGF receptor Human genes 0.000 description 1
108060006698 EGF receptor Proteins 0.000 description 1
238000012286 ELISA Assay Methods 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
102000009024 Epidermal Growth Factor Human genes 0.000 description 1
102400001368 Epidermal growth factor Human genes 0.000 description 1
101800003838 Epidermal growth factor Proteins 0.000 description 1
241000701959 Escherichia virus Lambda Species 0.000 description 1
230000004668 G2/M phase Effects 0.000 description 1
102000013446 GTP Phosphohydrolases Human genes 0.000 description 1
108091006109 GTPases Proteins 0.000 description 1
208000032612 Glial tumor Diseases 0.000 description 1
206010018338 Glioma Diseases 0.000 description 1
239000004366 Glucose oxidase Substances 0.000 description 1
108010015776 Glucose oxidase Proteins 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
102000009465 Growth Factor Receptors Human genes 0.000 description 1
108010009202 Growth Factor Receptors Proteins 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
101710154606 Hemagglutinin Proteins 0.000 description 1
101000684275 Homo sapiens ADP-ribosylation factor 3 Proteins 0.000 description 1
101001130437 Homo sapiens Ras-related protein Rap-2b Proteins 0.000 description 1
102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
101710203526 Integrase Proteins 0.000 description 1
241000235058 Komagataella pastoris Species 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
102000007330 LDL Lipoproteins Human genes 0.000 description 1
108010007622 LDL Lipoproteins Proteins 0.000 description 1
108090001090 Lectins Proteins 0.000 description 1
102000004856 Lectins Human genes 0.000 description 1
108060001084 Luciferase Proteins 0.000 description 1
239000005089 Luciferase Substances 0.000 description 1
239000007987 MES buffer Substances 0.000 description 1
108060004795 Methyltransferase Proteins 0.000 description 1
241000699660 Mus musculus Species 0.000 description 1
229930193140 Neomycin Natural products 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
101710163270 Nuclease Proteins 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
239000005642 Oleic acid Substances 0.000 description 1
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
108020005187 Oligonucleotide Probes Proteins 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
108091008606 PDGF receptors Proteins 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
102100035593 POU domain, class 2, transcription factor 1 Human genes 0.000 description 1
101710084414 POU domain, class 2, transcription factor 1 Proteins 0.000 description 1
239000002033 PVDF binder Substances 0.000 description 1
102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 1
241000276498 Pollachius virens Species 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
101710176177 Protein A56 Proteins 0.000 description 1
102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
101100084022 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) lapA gene Proteins 0.000 description 1
239000012083 RIPA buffer Substances 0.000 description 1
108091008103 RNA aptamers Proteins 0.000 description 1
239000012980 RPMI-1640 medium Substances 0.000 description 1
102100031421 Ras-related protein Rap-2b Human genes 0.000 description 1
102220467227 Receptor tyrosine-protein kinase erbB-2_A1216D_mutation Human genes 0.000 description 1
108700008625 Reporter Genes Proteins 0.000 description 1
108091027981 Response element Proteins 0.000 description 1
102000006382 Ribonucleases Human genes 0.000 description 1
108010083644 Ribonucleases Proteins 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
241000607142 Salmonella Species 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
108010003723 Single-Domain Antibodies Proteins 0.000 description 1
241000256248 Spodoptera Species 0.000 description 1
241000187747 Streptomyces Species 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
239000005864 Sulphur Substances 0.000 description 1
108091008874 T cell receptors Proteins 0.000 description 1
102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
108020005038 Terminator Codon Proteins 0.000 description 1
239000004098 Tetracycline Substances 0.000 description 1
108010022394 Threonine synthase Proteins 0.000 description 1
101710120037 Toxin CcdB Proteins 0.000 description 1
102000004338 Transferrin Human genes 0.000 description 1
108090000901 Transferrin Proteins 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
239000013504 Triton X-100 Substances 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 1
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
238000002441 X-ray diffraction Methods 0.000 description 1
JOOSFXXMIOXKAZ-UHFFFAOYSA-H [Au+3].[Au+3].[O-]C(=O)CC(S)C([O-])=O.[O-]C(=O)CC(S)C([O-])=O.[O-]C(=O)CC(S)C([O-])=O Chemical compound [Au+3].[Au+3].[O-]C(=O)CC(S)C([O-])=O.[O-]C(=O)CC(S)C([O-])=O.[O-]C(=O)CC(S)C([O-])=O JOOSFXXMIOXKAZ-UHFFFAOYSA-H 0.000 description 1
230000001594 aberrant effect Effects 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
239000008351 acetate buffer Substances 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
239000008272 agar Substances 0.000 description 1
238000007818 agglutination assay Methods 0.000 description 1
239000000556 agonist Substances 0.000 description 1
230000003281 allosteric effect Effects 0.000 description 1
230000004075 alteration Effects 0.000 description 1
230000006229 amino acid addition Effects 0.000 description 1
229960000723 ampicillin Drugs 0.000 description 1
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
238000005571 anion exchange chromatography Methods 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
230000009830 antibody antigen interaction Effects 0.000 description 1
210000000628 antibody-producing cell Anatomy 0.000 description 1
229940041181 antineoplastic drug Drugs 0.000 description 1
229960004405 aprotinin Drugs 0.000 description 1
210000004082 barrier epithelial cell Anatomy 0.000 description 1
238000002306 biochemical method Methods 0.000 description 1
238000001574 biopsy Methods 0.000 description 1
229960002685 biotin Drugs 0.000 description 1
235000020958 biotin Nutrition 0.000 description 1
239000011616 biotin Substances 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
244000309466 calf Species 0.000 description 1
230000005773 cancer-related death Effects 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
231100000357 carcinogen Toxicity 0.000 description 1
239000003183 carcinogenic agent Substances 0.000 description 1
238000005277 cation exchange chromatography Methods 0.000 description 1
230000021164 cell adhesion Effects 0.000 description 1
230000025084 cell cycle arrest Effects 0.000 description 1
230000030833 cell death Effects 0.000 description 1
230000003915 cell function Effects 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
230000003833 cell viability Effects 0.000 description 1
230000008614 cellular interaction Effects 0.000 description 1
239000000919 ceramic Substances 0.000 description 1
150000001805 chlorine compounds Chemical class 0.000 description 1
239000007979 citrate buffer Substances 0.000 description 1
238000003271 compound fluorescence assay Methods 0.000 description 1
238000010205 computational analysis Methods 0.000 description 1
230000030944 contact inhibition Effects 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
231100000517 death Toxicity 0.000 description 1
238000003936 denaturing gel electrophoresis Methods 0.000 description 1
229960003964 deoxycholic acid Drugs 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
102000004419 dihydrofolate reductase Human genes 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
238000009826 distribution Methods 0.000 description 1
230000007783 downstream signaling Effects 0.000 description 1
238000009509 drug development Methods 0.000 description 1
238000007877 drug screening Methods 0.000 description 1
241001493065 dsRNA viruses Species 0.000 description 1
229940121647 egfr inhibitor Drugs 0.000 description 1
238000004520 electroporation Methods 0.000 description 1
238000010828 elution Methods 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
230000007515 enzymatic degradation Effects 0.000 description 1
229940116977 epidermal growth factor Drugs 0.000 description 1
230000004890 epithelial barrier function Effects 0.000 description 1
108700020302 erbB-2 Genes Proteins 0.000 description 1
238000012869 ethanol precipitation Methods 0.000 description 1
210000003527 eukaryotic cell Anatomy 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000011536 extraction buffer Substances 0.000 description 1
210000000416 exudates and transudate Anatomy 0.000 description 1
235000013861 fat-free Nutrition 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
238000001914 filtration Methods 0.000 description 1
229940047127 fiore Drugs 0.000 description 1
238000011354 first-line chemotherapy Methods 0.000 description 1
238000000684 flow cytometry Methods 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
238000012817 gel-diffusion technique Methods 0.000 description 1
238000002523 gelfiltration Methods 0.000 description 1
238000001415 gene therapy Methods 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
208000005017 glioblastoma Diseases 0.000 description 1
229940116332 glucose oxidase Drugs 0.000 description 1
235000019420 glucose oxidase Nutrition 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
230000036541 health Effects 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
238000012872 hydroxylapatite chromatography Methods 0.000 description 1
238000003384 imaging method Methods 0.000 description 1
238000002649 immunization Methods 0.000 description 1
239000012133 immunoprecipitate Substances 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
229910052738 indium Inorganic materials 0.000 description 1
APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 1
230000006698 induction Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
206010022000 influenza Diseases 0.000 description 1
ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
230000004068 intracellular signaling Effects 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
238000011901 isothermal amplification Methods 0.000 description 1
229960000318 kanamycin Drugs 0.000 description 1
229930027917 kanamycin Natural products 0.000 description 1
SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
229930182823 kanamycin A Natural products 0.000 description 1
HWSZZLVAJGOAAY-UHFFFAOYSA-L lead(II) chloride Chemical compound Cl[Pb]Cl HWSZZLVAJGOAAY-UHFFFAOYSA-L 0.000 description 1
239000002523 lectin Substances 0.000 description 1
238000007834 ligase chain reaction Methods 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
230000007774 longterm Effects 0.000 description 1
HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
201000005249 lung adenocarcinoma Diseases 0.000 description 1
230000002934 lysing effect Effects 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
108010082117 matrigel Proteins 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
239000002923 metal particle Substances 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
239000011325 microbead Substances 0.000 description 1
239000003094 microcapsule Substances 0.000 description 1
238000013508 migration Methods 0.000 description 1
230000005012 migration Effects 0.000 description 1
239000008267 milk Substances 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
210000004080 milk Anatomy 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
238000000329 molecular dynamics simulation Methods 0.000 description 1
229960004927 neomycin Drugs 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
230000036963 noncompetitive effect Effects 0.000 description 1
238000001613 nuclear run-on assay Methods 0.000 description 1
108091008104 nucleic acid aptamers Proteins 0.000 description 1
238000011580 nude mouse model Methods 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
239000002751 oligonucleotide probe Substances 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
150000002894 organic compounds Chemical class 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
150000002902 organometallic compounds Chemical class 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
229960002087 pertuzumab Drugs 0.000 description 1
101150009573 phoA gene Proteins 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
229940080469 phosphocellulose Drugs 0.000 description 1
239000003934 phosphoprotein phosphatase inhibitor Substances 0.000 description 1
239000013600 plasmid vector Substances 0.000 description 1
125000003367 polycyclic group Chemical group 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
229920002981 polyvinylidene fluoride Polymers 0.000 description 1
239000013641 positive control Substances 0.000 description 1
229940124606 potential therapeutic agent Drugs 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
230000009696 proliferative response Effects 0.000 description 1
238000000159 protein binding assay Methods 0.000 description 1
238000004451 qualitative analysis Methods 0.000 description 1
238000004445 quantitative analysis Methods 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000004043 responsiveness Effects 0.000 description 1
238000007894 restriction fragment length polymorphism technique Methods 0.000 description 1
238000012552 review Methods 0.000 description 1
229920002477 rna polymer Polymers 0.000 description 1
238000005096 rolling process Methods 0.000 description 1
102220197854 rs1057519738 Human genes 0.000 description 1
102220242766 rs144437882 Human genes 0.000 description 1
102200050562 rs45611935 Human genes 0.000 description 1
210000003079 salivary gland Anatomy 0.000 description 1
235000019515 salmon Nutrition 0.000 description 1
239000012723 sample buffer Substances 0.000 description 1
238000013341 scale-up Methods 0.000 description 1
238000007423 screening assay Methods 0.000 description 1
230000028327 secretion Effects 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
230000011664 signaling Effects 0.000 description 1
238000002741 site-directed mutagenesis Methods 0.000 description 1
238000002791 soaking Methods 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
CMZUMMUJMWNLFH-UHFFFAOYSA-N sodium metavanadate Chemical compound [Na+].[O-][V](=O)=O CMZUMMUJMWNLFH-UHFFFAOYSA-N 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
241000894007 species Species 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
238000013517 stratification Methods 0.000 description 1
239000013589 supplement Substances 0.000 description 1
238000004114 suspension culture Methods 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
230000008685 targeting Effects 0.000 description 1
229910052713 technetium Inorganic materials 0.000 description 1
229960002180 tetracycline Drugs 0.000 description 1
229930101283 tetracycline Natural products 0.000 description 1
235000019364 tetracycline Nutrition 0.000 description 1
150000003522 tetracyclines Chemical class 0.000 description 1
238000010257 thawing Methods 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
238000005382 thermal cycling Methods 0.000 description 1
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
229940033663 thimerosal Drugs 0.000 description 1
238000004448 titration Methods 0.000 description 1
235000013619 trace mineral Nutrition 0.000 description 1
239000011573 trace mineral Substances 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
230000005026 transcription initiation Effects 0.000 description 1
230000005030 transcription termination Effects 0.000 description 1
238000010361 transduction Methods 0.000 description 1
230000026683 transduction Effects 0.000 description 1
239000012096 transfection reagent Substances 0.000 description 1
238000012546 transfer Methods 0.000 description 1
239000012581 transferrin Substances 0.000 description 1
229960000575 trastuzumab Drugs 0.000 description 1
229940108519 trasylol Drugs 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
229940038773 trisodium citrate Drugs 0.000 description 1
229910052722 tritium Inorganic materials 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
239000004474 valine Substances 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
229910000166 zirconium phosphate Inorganic materials 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Toxicology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Cell Biology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Apparatus Associated With Microorganisms And Enzymes (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Investigating Or Analysing Biological Materials (AREA)

CA002575462A 2004-07-30 2005-07-29 Mutations dans des erb2 associee a des phenotypes cancereux Abandoned CA2575462A1 (fr)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US59253804P	2004-07-30	2004-07-30
GBGB0417107.0A GB0417107D0 (en)	2004-07-30	2004-07-30	Genes II
US60/592,538		2004-07-30
GB0417107.0		2004-07-30
PCT/GB2005/002976 WO2006010938A1 (fr)	2004-07-30	2005-07-29	Mutations dans des erb2 associee a des phenotypes cancereux

Publications (1)

Publication Number	Publication Date
CA2575462A1 true CA2575462A1 (fr)	2006-02-02

Family

ID=35106874

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002575462A Abandoned CA2575462A1 (fr)	2004-07-30	2005-07-29	Mutations dans des erb2 associee a des phenotypes cancereux

Country Status (7)

Country	Link
EP (1)	EP1771472A1 (fr)
JP (1)	JP2008515386A (fr)
AU (1)	AU2005266133A1 (fr)
CA (1)	CA2575462A1 (fr)
NO (1)	NO20065159L (fr)
NZ (1)	NZ551325A (fr)
WO (1)	WO2006010938A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2976294B1 (fr)	2011-06-10	2018-02-16	Universite De Nice Sophia Antipolis	Methode de prediction de la reponse a un traitement avec un agent bloquant her2
US11773449B2 (en)	2017-09-01	2023-10-03	The Hospital For Sick Children	Profiling and treatment of hypermutant cancer

2005
- 2005-07-29 WO PCT/GB2005/002976 patent/WO2006010938A1/fr not_active Ceased
- 2005-07-29 AU AU2005266133A patent/AU2005266133A1/en not_active Abandoned
- 2005-07-29 EP EP05767495A patent/EP1771472A1/fr not_active Withdrawn
- 2005-07-29 CA CA002575462A patent/CA2575462A1/fr not_active Abandoned
- 2005-07-29 NZ NZ551325A patent/NZ551325A/en not_active IP Right Cessation
- 2005-07-29 JP JP2007523153A patent/JP2008515386A/ja active Pending
2006
- 2006-11-09 NO NO20065159A patent/NO20065159L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
WO2006010938A1 (fr)	2006-02-02
EP1771472A1 (fr)	2007-04-11
AU2005266133A1 (en)	2006-02-02
JP2008515386A (ja)	2008-05-15
NZ551325A (en)	2009-11-27
NO20065159L (no)	2007-04-30

Legal Events

Date	Code	Title	Description
2010-05-28	EEER	Examination request
2012-07-30	FZDE	Dead

Publication	Publication Date	Title
US8580497B2 (en)	2013-11-12	Methods for detection of the oncogenic T1796A B-Raf mutation
US7198899B2 (en)	2007-04-03	Use of NRG4, or inhibitors thereof, in the treatment of colon and pancreatic cancers
US20020051990A1 (en)	2002-05-02	Novel gene targets and ligands that bind thereto for treatment and diagnosis of ovarian carcinomas
US20030044409A1 (en)	2003-03-06	Immunologic compositions and methods for studying and treating cancers expressing frizzled antigens
US20040096855A1 (en)	2004-05-20	Genes
US8962808B2 (en)	2015-02-24	EGFR-related polypeptides and methods of use
AU2012228544B2 (en)	2015-06-11	Single nucleotide polymorphisms in the promoter of VEGFA gene and their use as predictive markers for anti-VEGF treatments
Hayes et al.	2007	Identification and characterization of novel spliced variants of neuregulin 4 in prostate cancer
JP2008522162A (ja)	2008-06-26	Ｍｅｒの診断用および治療用の作用薬
US20080206248A1 (en)	2008-08-28	Mutations in ErbB2 associated with cancerous phenotypes
WO2003060111A2 (fr)	2003-07-24	Genes
CA2575462A1 (fr)	2006-02-02	Mutations dans des erb2 associee a des phenotypes cancereux
US20020061552A1 (en)	2002-05-23	Mammalian dishevelled-associated proteins
EP2141231B1 (fr)	2014-03-12	PROCÉDÉ D'INHIBITION DE SIGNALISATION PAR L'INTERMÉDIAIRE D'ErbB2, INHIBITEUR DE SIGNALISATION DESTINÉ À ÊTRE UTILISÉ DANS CE PROCÉDÉ, ET UTILISATION DE L'INHIBITEUR DE SIGNALISATION
ES2362745T3 (es)	2011-07-12	Mutaciones en el gen b-raf.
JP5208105B2 (ja)	2013-06-12	ＥｒｂＢ２を介するシグナル伝達経路のダウンレギュレーションの有無を判定する方法、抗癌剤による治療の要否の判断を補助する方法、およびシグナル伝達阻害剤
Lösch et al.	2004	Identification of a novel transmembrane protein (UKW): Association with invasive status of mammary carcinoma cell lines and expression in pancreatic carcinoma
US20030186232A1 (en)	2003-10-02	Human and non-human primate homologues of Nkd protein, nucleic acid sequences encoding, and uses thereof